MicroRNA-320a Suppresses Tumor Progression by Targeting PBX3 in Gastric Cancer and is Downregulated by DNA Methylation
Overview
Authors
Affiliations
Background: Ectopic expression of miRNAs promotes tumor development and progression. miRNA (miR)-320a is downregulated in many cancers, including gastric cancer (GC). However, the mechanism underlying its downregulation and the role of miR-320a in GC are unknown.
Aim: To determine expression and biological functions of miR-320a in GC and investigate the underlying molecular mechanisms.
Methods: Quantitative real-time polymerase chain reaction (PCR) was used to determine expression of miR-320a in GC cell lines and tissues. TargetScanHuman7.1, miRDB, and microRNA.org were used to predict the possible targets of miR-320a, and a dual luciferase assay was used to confirm the findings. Western blotting was used to detect the protein levels of pre-B-cell leukemia homeobox 3 (PBX3) in GC cells and tissue samples. Cell Counting Kit-8 proliferation, Transwell, wound healing, and apoptosis assays were performed to analyze the biological functions of miR-320a in GC cells. Methylation-specific PCR was used to analyze the methylation level of the miR-320a promoter CpG islands. 5-Aza-2'-deoxycytidine (5-Aza-CdR) and trichostatin A (TSA) were used to treat GC cells.
Results: miR-320a expression was lower in GC cell lines and tissues than in the normal gastric mucosa cell line GES-1 and matched adjacent normal tissues. miR-320a overexpression suppressed GC cell proliferation, invasion and migration, and induced apoptosis. PBX3 was a target of miR-320a in GC. The methylation level of the miR-320a promoter CpG islands was elevated and this was partly reversed by 5-Aza-CdR and TSA.
Conclusion: miR-320a acts as a tumor suppressor and inhibits malignant behavior of GC cells, partly by targeting PBX3. DNA methylation is an important mechanism associated with low expression of miR-320a.
Chen W, Chang T, Chou H, Cheng M, Hong J, Hsieh Y Int J Mol Sci. 2023; 24(11).
PMID: 37298699 PMC: 10253890. DOI: 10.3390/ijms24119748.
Li Y, Zou Y, Dai D World J Gastrointest Oncol. 2022; 14(6):1216-1217.
PMID: 35949221 PMC: 9244982. DOI: 10.4251/wjgo.v14.i6.1216.
miR-28-5p inhibits cholangiocarcinoma progression and predicts good prognosis of patients.
Chen T, Wang H, Yan H Cell Cycle. 2022; 21(19):2079-2090.
PMID: 35670491 PMC: 9467542. DOI: 10.1080/15384101.2022.2085359.
The regulation of PBXs and their emerging role in cancer.
Liu Y, Ao X, Zhou X, Du C, Kuang S J Cell Mol Med. 2022; 26(5):1363-1379.
PMID: 35068042 PMC: 8899182. DOI: 10.1111/jcmm.17196.
Huang C, Liu J, He L, Wang F, Xiong B, Li Y Bioengineered. 2021; 12(2):11738-11755.
PMID: 34895039 PMC: 8810175. DOI: 10.1080/21655979.2021.2009412.